Multiple endocrine neoplasia (MEN)-an overview and case report - Patient with sporadic bilateral pheochromocytoma, hyperparathyroidism and marfanoid habitus

Anticancer Research

Volumn 20, Issue 6 C, 2000, Pages 4877-4887

  Fassbender, W J ^a   Krohn Grimberghe, B ^a   Gortz B ^a   Litzlbauer, D ^a   Stracke, H ^a   Raue, F ^a   Kaiser, H E ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Adrenalectomy; Gene carrier; Hyperparathyroidism; Islet cell tumors; Medullary thyroid carcinoma; MEN I gene; Multiple endocrine neoplasia; Pheochromocytoma; Polyglandular autoimmune syndrome; Proto oncogene RET; Zollinger Ellison syndrome

Indexed keywords

CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; APUD CELL; AUTOSOMAL DOMINANT DISORDER; CARCINOGENESIS; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GASTRINOMA; GENE MUTATION; GENETIC SCREENING; HUMAN; HYPERPARATHYROIDISM; INCIDENCE; INSULINOMA; MALE; MARFAN SYNDROME; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; ONCOGENE RET; PANCREAS ISLET CELL TUMOR; PATHOGENESIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; SIPPLE SYNDROME; THYROID CARCINOMA; VON HIPPEL LINDAU DISEASE;

ADRENAL GLAND NEOPLASMS; ADULT; CALCITONIN; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERPARATHYROIDISM; MALE; MARFAN SYNDROME; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; PHEOCHROMOCYTOMA;

EID: 0034495762     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Zur normalen und pathologischen histologie der glandula thyreoidea, parathyreoidea und hypophysis
2. Multiple endocrine adenomas: Report of 8 cases in which the parathyroids, pituitary and pancreatic islets were involved
3. Genetic aspects of adenomatosis of endocrine glands
4. The association of pheochromocytoma with carcinoma of the thyroid gland
5. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1
6. Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimobranchial C Cells and calcitonin
7. Study of a kindred with pheochromocytoma, medullary carcinoma, hyperparathyroidism and Cushing's disease: Multiple endocrine neoplasia, type 2
8. Familial multiple endocrine adenomatosis: Multiple endocrine neoplasia, type I
9. Multiple endocrine adenomatosis (type I) and familial hyperparathyroidism
10. Familial multiple endocrine neoplasia syndromes: Components, classification, and nomenclature
11. Multiple endocrine neoplasia type I gene maps to chromosome 11 and is lost in insulinoma
12. Linkage analysis of multiple endocrine neoplasia type I with INT2 and other markers on chromosome 11
13. Linked markers flanking the gene for multiple endocrine neoplasia type 2A
14. Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type I
15. RET proto-oncogene in the developement of human cancer
16. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmatic cysteines
17. Multiple endocrine neoplasia type 2 (MEN2) in children and adolescents
18. Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1
19. Circulating fibroblast growth factor- like substance in familial multiple endocrme neoplasia type 1
20. Inreased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type 1: Relation to pituitary tumor
21. Parathyroid hormone-related protein in hypercalcemia of malignancy
22. Surgical management of hyperinsulinism in the multiple endocrine neoplasia, type 1 syndrome
23. Islet cell tumors in von Hippel-Lindau disease: Increased prevalence and relationship to the multiple endocrine neoplasias
24. Islet cell tumor in von Hippel-Lindau disease
25. Current management of Zollinger-Ellison syndrome
26. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid
27. Mutations in the human Ca(2+)-sensing receptor gene that cause familial hypocalciuric hypercalcemia
28. Serum gastrin level is increased by chronic hypercalcemia of parathyroid or nonparathyroid origin
29. A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: Five years experience
30. Multiple endocrine neoplasia type 1: Gastrinomas, pancreatic neoplasms, microcarcinoids, the Zollinger-Ellison syndrome, lymph nodes, and hepatic metastases
31. Nonrandom expression of polypeptide hormones in pancreatic endocrine tumors: An immunohistochemical study in a case of multiple islet cell neoplasia
32. Beta-islet cell tumors of the pancreas: Results 1 of a study on 1,067 cases
33. Glucagonoma as part of the polyglandular adenoma syndrome
34. Multiple endocrine neoplasia, type 1, with pancreatic cholera
35. Carcinoid tumor of the pancreas causing the diarrhreogenic syndrome: Report of a case combined with multiple endocrine neoplasia, type 1
36. Management of individual tumor syndromes: Pituitary neoplasia
37. Thymus carcinoid in multiple endocrine neoplasms type I
38. Clinical experience over 48 years with pheochromocytoma
39. Multiple endocrine neoplasia type I: Assessment of laboratory tests to screen for the gene in a large kindred
40. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia typetype I
41. Gastrinoma: Factors influencing prognosis
42. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type I and the Zollinger-Ellison syndrome
43. Autogenous parathyroid grafts for generalized primary parathyroid hyperplasia: Contrasting outcome in sporadic hyperplasia versus multipleendocrineneoplasiatypeI
44. Parathyroid auto-transplantation in primay parathyroid hyperplasia
45. Use of omeprazole in patients with Zollinger- Ellison syndrome
46. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells
47. The role of surgical treatment in Zollinger-Ellison syndrome
48. Total pancreatectomy in the MEN I syndrome
49. The surgical treatment of occult insulinomas: A review of the problem
50. Somatostatin and somatostatin analogue (SMS 201 -995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut
51. Prospective screening in multiple endocrine neoplasia type 1
52. Multiple endocrine neoplasia type 1: Clinical features and screening
53. The role of molecular genetics in screening for multiple endocrine neoplasia type 1
54. Genetic and clinical characteristics of multiple endocrine neoplasia type 1
55. Practical guidelines for DNA-based testing in multiple endocrine neoplasia type 1
56. Studies in familial (medullary) thyroid, carcinoma
57. Medullary carcinoma of the thyroid gland
58. Natural history of familial medullary thyroid carcinoma: Effect of a program for early diagnosis
59. Isolation of regio-specific cosmids by hybridization with microdissection clones from human chromosome 10ql 1.1-q21.1
60. A primary genetic linkage map of chromosome 10. Human gene mapping 9: Ninth International Workshop on Human Gene Mapping
61. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
62. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (MEN 2A)
63. Linkage of the multiple endocrine neoplasia type 2B gene (MEN2B) to chromosome 10 markers linked to MEN 2A
64. Familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2B map to the same region of chromosome 10 as multiple endocrine neoplasia type 2A
65. Clonal origin of inherited medullary thyroid carcinoma and pheochromocytoma
66. Current diagniosis and management of medullary thyroid carcinoma
67. Analysis of RET proto-oncogene point mutations distinduishes heritable from nonheritable medullary thyroid carcinomas
68. Medullary thyroid carcinoma
69. Tumor markers of medullary thyroid carcinoma
70. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a: An 18-year experience
71. Relevance of RET proto-oncogen mutations in sporadic medullary thyroid carcinoma
72. Identification of the cys 634-to-tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis
73. Differences between sporadic pheochromocytoma and pheochromocytoma in multiple endocrine neopasia, type 2
74. Unilateral laparascopic adrenalectomy followed by contralateral retroperitoneoscopic partial adrenalectomy in a patient with multiple endocrine neoplasia typ 2a syndrome
75. Pheochromocytoma: Current diagnostic methods
76. Differences between sporadic and multiple endocrine neoplasia type 2 Apheochromocytoma
77. Prevalence of pheochromocytoma and v hyperparathyroidism in multiple endocrine neoplasia type 2A: Results of long-term follow-up
78. Familial hyperparathyroidism
79. The parathyroid glands in multiple endocrine neoplasia type 2b
80. Mucosal neuroma, pheochromocytoma and medullary thyroid carcinoma: Multiple endocrine neoplasia type 3
81. Occurrence of MEN 2a in familial Hirschsprung s disease: A new indication for genetic testing of the RET proto-oncogene
82. A gene for Hirschsprung disease (megacolon) in the pericentromeric region of human chromosome 10
83. A gene for Hirschsprung disease maps to the proximal long arm of chromosome 10
84. Neuromas and prominent corneal nerves without MEN 2B
85. Studies of short-term secretion of peptides produced by alternative RNA processing
86. Somatostatin production by a human medullary thyroid carcinoma cell line
87. Secretion of chromogranin A by peptide-producing endcrine neoplasms
88. Somatostatin receptor scintigraphy for early detection of regional and disstant metastases of medullary carcinoma of the thyroid
89. Spectrum of pheochromocytoma in multiple endocrine neoplasia: A scintigraphic portrayal using 131-I-metaiodobenzylguanidine
90. Nuclear medicine imaging of pheochromocytoma and neuroblastoma
91. Iodine-131 MIBG imaging in multiple endocrine neoplasia type 2B
92. The early diagnosis of medullary carcinoma of the thyroid gland in patients with multiple endocrine neoplasia type II
93. Results of early thyroidectomy for medullary thyroid carcinoma in children with multiple endocrine neoplasia type 2
94. Changing trends in the management of pheochromocytoma
95. Current perspectives in the surgery of multiple endocrine neoplasias
96. Multiple endocrine neoplasia type 2 (MEN 2) - Prognostic and therapeutic aspects
97. Detection of RET proto-oncogene point mutations in paraffin-embedded pheochromocytoma specimens by nonradioactive single-strand conformation polymorphism analysis and direct sequencing
98. Mutation of a specific codon of the ret proto-oncogene in the multiple endocrine neoplasia type 2A / cutaneous lichen amyloidosis syndrome
99. Point mutation within the tyrosinkinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours
100. Management of occult medullary thyroid carcinoma: Evidenced only by serum calcitonin level elevations after apparently adequate neck operations
101. Total thyroidectomy for occult familial medullary carcinoma of the thyroid in children
102. Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: High sensitivity of selective venous catheterization
103. Autoimmune polyglandular syndromes
104. Clinical variation of autoimmune polyendocrinopathy - Candidiasis - Ectodermal dystrophy (APECED) in a series of 68 patients
105. Two types of autoimmuno Addison s disease associated with different polyglandular autoimmune syndromes
106. Von Hippel-Lindau disease: Strategies in early detection (renal-, adrenal-, pancreatic masses)
107. Von Hippel-Lindau disease: Recent progress in genetics and patient management